ID Biomedical Corporation announced today it has been advised by the United States Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) that the Company's Influenza Viru
The U.S. Food and Drug Administration (FDA) advisory panel has declared that three asthma drugs are safe enough to stay on the market, after concerns that in rare cases they raise the risk of severe asthm
Doctors are beginning the first test in the United States of a vaccine designed to protect people against one form of bird flu should an outbreak of the virus occur in humans. While the vaccine under study is not designed to protect against the precise
India's Ranbaxy Laboratories has announced that it has received tentative approval from the U.S. Food and Drug Administration (USFDA) to manufacture and market Zidovudine Tablets USP, 300 mg.
Bioniche Life Sciences has announced that its Pharma Division has launched Sotradecol(R) Injection (Sodium Tetradecyl Sulfate Injection) in the United States. Sotradecol is approved by the U.
Now that senators Patty Murray of Washington and Hillary Clinton of New York, have dropped their objections to acting FDA Commissioner Lester Crawford becoming the permanent commissioner, approval for the sale of the Plan B "morning-after" contraceptiv
The U.S. Food and Drug Administration (FDA) is investigating reports of the deaths of patients who were using pain patches that contain the narcotic fentanyl.The fentanyl patches made by Johnson &
Karen Ignagni, President and CEO of America's Health Insurance Plans (AHIP), made the following statement regarding HHS Secretary Tommy G. Thompson's announcement today of the start of the prescription drug card program:
Vertex Pharmaceuticals has announced that its collaborator, GlaxoSmithKline (GSK), has received fast track designation for the HIV protease inhibitor (PI
The American Society for Aesthetic Plastic Surgery (ASAPS) has announced that patients need to be wary of "bargain" injectables or other treatments that are not approved by the United States Food and
The Medicines and Healthcare products Regulatory Agency (MHRA) will publish anonymous data on suspected adverse drug reactions on their website. Researchers will also be able to access more detailed data and measures will be put in place to prevent potential abuse of the information. Every request will be reviewed by an independent commitee to make sure it is ethically and scientifically sound and protects patient confidentiality.
The first pilots of patients directly reporting unexpected effects of drugs to the regulator were also launched. Forms to report unexpected drug reactions will available in 4000 GP surgeries across the UK and patients will also be able to make reports online.
Health Minister Lord Warner said:
"The Yellow Card System is recognised to be one of the best spontaneous reporting schemes for adverse drug reactions in the world. The measures I have announced today will help make it even better. I hope we can expand the scheme being piloted nationally later in the year.
The data generated through the scheme can be used to further research and improve drug safety in the UK - patients can see the information used to make decisions about medicines safety and researchers can use this important resource to aid research. Enabling patients to directly report unexpected drug reactions allows them to play their part in making medicines safer and help the experts better monitor drug safety and protect public health".
The new measures are key recommendations made by experts who reviewed the yellow card scheme last year and a public consultation. The Chair of the review, former deputy Chief Medical Officer, Dr Jeremy Metters has agreed to chair the group advising the MHRA on setting up these new measures.
Chairman of the MHRA, Sir Alasdair Breckenridge said:
"The Yellow Card Scheme is an important way that the MHRA monitors drug safety. It is only right that others can also benefit from the data. Research based on Yellow Card data could have enormous public health benefits and by enabling researchers to access the data we will be playing our part in promoting this important research. I am also delighted that Dr Metter's has agreed to help advise on opening access to the scheme".
http://www.dh.gov.uk/